
Novavax CEO Stanley Erck at the White House in 2020 (Andrew Harnik, AP Images)
As fears mount over J&J and AstraZeneca, Novavax enters a shaky spotlight
As concerns rise around the J&J and AstraZeneca vaccines, global attention is increasingly turning to the little, 33-year-old, productless, bankruptcy-flirting biotech that could: Novavax. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.